Scarica l'app Stockscreener
51.88
0.91%
0.47
Pre-mercato:
52.64
0.76
+1.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$51.41
Aprire:
$51.16
Volume 24 ore:
858.67K
Relative Volume:
0.58
Capitalizzazione di mercato:
$4.35B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-13.83
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
-5.74%
1M Prestazione:
+2.27%
6M Prestazione:
+84.76%
1 anno Prestazione:
+131.81%
Intervallo 1D:
$51.08
$52.60
Intervallo di 1 settimana:
$51.08
$57.35
Portata 52W:
$21.02
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
51.88 | 4.35B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 3.3%Time to Sell? - MarketBeat
Don't Ignore The Insider Selling In Akero Therapeutics - simplywall.st
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 2,803 Shares of Stock - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 919 Shares of Stock - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 2,493 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $127,332.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $151,387.96 in Stock - MarketBeat
Rhumbline Advisers Purchases 5,001 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Millennium Management LLC Lowers Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Targ - GuruFocus
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by SG Americas Securities LLC - MarketBeat
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased - MSN
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $668,625.00 in Stock - MarketBeat
Investors Buy Large Volume of Call Options on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,376,000.00 in Stock - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 37,837 Shares of Stock - MarketBeat
Akero Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
(AKRO) Technical Data - news.stocktradersdaily.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Transcript : Akero Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 02 - MarketScreener
Day 8 of Gains Streak for Akero Therapeutics Stock with 21% Return (vs. 97% YTD) [6/9/2025] - Trefis
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail
Akero Therapeutics' Chief Scientific Officer Sells Shares - TradingView
Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stoc - GuruFocus
Rumor Fuels Akero Therapeutics (AKRO) Stock Movement | AKRO Stock News - GuruFocus
Ameriprise Financial Inc. Purchases Shares of 15,172 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 4,000 Shares - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2025-06-08 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Bank of America Corp DE Sells 93,294 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Day 7 of Gains Streak for Akero Therapeutics Stock with 20% Return (vs. 95% YTD) [6/6/2025] - Trefis
Ionis Pharmaceuticals (NASDAQ:IONS) versus Akero Therapeutics (NASDAQ:AKRO) Financial Contrast - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - ACCESS Newswire
Ameriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics Elects New Directors at Annual Meeting - TipRanks
Two Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akero Therapeutics Inc Azioni (AKRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cheng Andrew | President and CEO |
Jun 18 '25 |
Sale |
54.84 |
6,620 |
363,041 |
549,867 |
| Gangloff Scott A. | Chief Technology Officer |
Jun 18 '25 |
Sale |
54.84 |
848 |
46,504 |
23,452 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Jun 20 '25 |
Sale |
54.59 |
875 |
47,766 |
31,698 |
| Rolph Timothy | Chief Scientific Officer |
Jun 18 '25 |
Sale |
54.84 |
1,129 |
61,914 |
166,234 |
| White William Richard | Chief Financial Officer |
Jun 18 '25 |
Sale |
54.84 |
1,634 |
89,609 |
57,521 |
| Yale Catriona | Chief Development Officer |
Jun 18 '25 |
Sale |
54.84 |
1,633 |
89,554 |
90,598 |
| Young Jonathan | Chief Operating Officer |
Jun 18 '25 |
Sale |
54.84 |
1,453 |
79,683 |
196,594 |
| Yale Catriona | Chief Development Officer |
Jun 16 '25 |
Option Exercise |
21.10 |
10,000 |
211,000 |
102,231 |
| Yale Catriona | Chief Development Officer |
Jun 16 '25 |
Sale |
54.23 |
10,000 |
542,306 |
92,231 |
| Lamy Patrick | Senior VP, Commercial Strategy |
Jun 16 '25 |
Option Exercise |
19.87 |
2,000 |
39,740 |
34,573 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):